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Summary 
Background Metformin might reduce insulin requirement and improve glycaemia in patients 
with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to 
investigate whether metformin treatment (added to titrated insulin therapy) reduced 
atherosclerosis, as measured by progression of common carotid artery intima-media thickness 
(cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease. 
Methods REMOVAL was a double-blind, placebo-controlled trial undertaken at 23 hospital 
diabetes clinics in five countries (Australia, Canada, Denmark, the Netherlands, and the UK). 
Adults aged 40 years and older with type 1 diabetes of at least 5 years' duration and at least three 
of ten specific cardiovascular risk factors were randomly assigned (via an interactive voice 
response system) to oral metformin 1000 mg twice daily or placebo. Participants and site staff 
were masked to treatment allocation. The primary outcome was averaged mean far-wall cIMT, 
quantified annually for 3 years, analysed in a modified intention-to-treat population (all 
randomly assigned participants with post-randomisation data available for the outcome of 
interest at any given timepoint, irrespective of subsequent adherence or study participation), 
using repeated measures regression. Secondary outcomes were HbA1c, LDL cholesterol, 
estimated glomerular filtration rate (eGFR), incident microalbuminuria (not reported), incident 
retinopathy, bodyweight, insulin dose, and endothelial function, also analysed in all participants 
with post-randomisation data available for the outcome of interest at any given timepoint. This 
trial is registered with ClinicalTrials.gov, number NCT01483560. 
Findings Between Dec 14, 2011, and June 24, 2014, 493 participants entered a 3 month run-in to 
optimise risk factor and glycaemic control (single-blind placebo in the final month). Of 428 
randomly assigned patients, 219 were allocated to metformin and 209 to placebo. Progression of 
mean cIMT was not significantly reduced with metformin (−0·005 mm per year, 95% CI −0·012 
to 0·002; p=0·1664), although maximal cIMT (a prespecified tertiary outcome) was significantly 
reduced (−0·013 mm per year, −0·024 to −0·003; p=0·0093). HbA1c (mean 8·1% [SD 0·9] for 
metformin and 8·0% [0·8] for placebo at baseline) was reduced on average over 3 years by 
metformin (−0·13%, 95% CI −0·22 to −0·037; p=0·0060), but this was accounted for by a 
reduction at the 3-month timepoint (−0·24%, −0·34 to −0·13; p<0·0001) that was not sustained 
thereafter (p=0·0163 for visit-by-treatment interaction). Bodyweight (−1·17 kg, 95% CI −1·66 to 
−0·69; p<0·0001) and LDL cholesterol (−0·13 mmol/L, −0·24 to −0·03; p=0·0117) were 
reduced with metformin over 3 years of treatment, and eGFR was increased (4·0 mL/min per 
1·73m2, 2·19 to 5·82; p<0·0001). Insulin requirement was not reduced on average over 3 years 
(−0·005 units per kg, 95% CI −0·022 to 0·012; p=0·545), but there was a significant visit-by-
treatment interaction (p=0·0018). There was no effect on endothelial function as measured by 
reactive hyperaemia index, or on retinopathy. Discontinuation of treatment in 59 (27%) 
participants on metformin versus 26 (12%) on placebo (p=0·0002) was mainly due to an excess 
of gastrointestinal adverse effects, and there was no increase in hypoglycaemia with metformin. 
Five deaths occurred among patients allocated to metformin and two occurred among those 
allocated to placebo; none were judged by site principal investigators to be related to study 
medication. 
Interpretation These data do not support use of metformin to improve glycaemic control in 
adults with long-standing type 1 diabetes as suggested by current guidelines, but suggest that it 
might have a wider role in cardiovascular risk management. 
Funding JDRF. 
  
RESEARCH IN CONTEXT 
Evidence before this study 
In our 2010 systematic review and meta-analysis, we captured all publications on type 1 diabetes 
and metformin for any outcomes in PubMed (from Jan 1, 1950, to Oct 6, 2009) and Embase (Jan 
1, 1974, to Oct 6, 2009) using medical search headings (MeSH): 1. ‘Diabetes Mellitus, Type 1’ 
[MeSH]; 2. (DIABET*) AND (TYPE 1 [TW] OR IDDM [TW]); OR (‘INSULIN 
DEPENDENT’ not ‘NON-INSULIN DEPENDENT’); 3. 1 OR 2; 4. ‘Metformin’ [MeSH]; 5. 
Metformin [TW]; 6. 4 OR 5. The search was run by two independent researchers who manually 
searched publications and their citations and extracted data from all that were considered 
potentially relevant. Additionally, we searched for ongoing and unpublished trials in the 
following sources: Cochrane Library 2009 issue 1; Science Citation Index meeting abstracts 
1980–2008 (which includes the European Association for the Study of Diabetes and American 
Diabetes Association meetings 1980 to October, 2008, Diabetes UK meeting abstracts 2002–08, 
and US Endocrine Society Abstracts 2005–08), the National Research Register, and 
www.controlled-trials.com. We identified only 192·8 participant-years of small, short-term, and 
therefore low-quality trials of metformin in patients with type 1 diabetes. There was evidence for 
a reduction in insulin dose requirement by about 6·6 units per day (pooled estimate) when 
metformin was added to insulin treatment. We noted bodyweight reduction with metformin in 
three of six studies and HbA1c reduction in four of seven studies, but could not calculate pooled 
estimates because of heterogeneity. Only results from the largest trial (n=100), in which only a 
third of participants were on statin therapy, showed lowering of LDL cholesterol with 
metformin. Since our meta-analysis, several further small trials of metformin in type 1 diabetes 
have been reported, but also a larger (n=140), 6 month trial by the US T1D Exchange in 140 
overweight and obese adolescents. The results of the T1D Exchange trial showed bodyweight 
reduction with metformin, a similar reduction in insulin dose requirement as in our systematic 
review, no reduction in LDL cholesterol, and improved glycaemic control at 3 months, but not at 
6 months. Despite the undoubted relevance of cardiovascular disease in patients with type 1 
diabetes, no previous trials of any intervention have been done with either clinical or 
intermediate cardiovascular outcomes. 
 
Added value of this study 
REMOVAL, the largest and longest trial of metformin in type 1 diabetes to date, confirms 
favourable effects on bodyweight and supports previous evidence of reduced insulin dose 
requirement, as reported in our meta-analysis and more recently in the T1D Exchange Study. It is 
the first study to show a sustained reduction in LDL cholesterol in middle-aged individuals with 
type 1 diabetes treated to target with statin therapy. It is also the first to indicate a possible 
reduction in atherosclerosis progression with metformin in type 1 diabetes, based on a surrogate 
outcome of common carotid intima-media thickness, although this finding was based on a 
tertiary rather than primary outcome. 
 
Implications of all the available evidence 
Our results provide a more rational basis for prescribing metformin, an inexpensive oral therapy, 
in patients with type 1 diabetes. Current guidelines in the UK and the USA recommend it for 
patients who are overweight or obese to reduce insulin dose requirement and improve glucose 
control. We identified a transient improvement in glycaemia that reverted to baseline with insulin 
dose reduction and identified no suggestion of greater benefit in overweight or obese patients. 
Type 1 diabetes guidelines should therefore be revised to reflect the absence of a sustained effect 
of adjunctive metformin on glycaemia and to remove the suggestion of particular efficacy in 
patients with a BMI greater than 25 kg/m2. Since larger and longer trials to investigate the effect 
of metformin on clinical cardiovascular outcomes in type 1 diabetes are unlikely to be done in 
the medium term, treatment decisions will have to be based on interpretation of the existing 
evidence. Rather than a role in glycaemic control, our findings suggest that long-term use of 
metformin in type 1 diabetes might reduce the long-term risk of cardiovascular disease via small 
but sustained reductions in bodyweight and LDL cholesterol. 
  
Introduction 
Cardiovascular disease (CVD) is a major cause of reduced life expectancy in patients with type 1 
diabetes and CVD is more than twice as common in people with type 1 diabetes as in the 
background population.1,2 Results from the Diabetes Control and Complications Trial (DCCT) 
and its post-randomisation follow-up study (Epidemiology of Diabetes and its Complications 
[EDIC]) showed that intensive glucose control in patients with type 1 diabetes reduces the onset 
and progression of microvascular and cardiovascular complications.3 However, in most countries 
more than 30% of adults with type 1 diabetes have poor glycaemic control;4 furthermore, many 
patients are overweight or obese,5 and, on the basis of data from Scotland, more than 60% of 
patients aged 40–59 years have poorly controlled cholesterol.1 
US and UK guidelines recommend adding metformin, an inexpensive drug treatment, to insulin 
in overweight or obese individuals with type 1 diabetes to improve blood glucose control and 
reduce insulin dose requirement.6,7 This advice is based partly on findings from our meta-
analysis of short-term and heterogeneous studies in which metformin was shown to reduce 
insulin requirement with possible benefits on bodyweight and HbA1c.
8 However, metformin is 
not widely used for this off-label indication; the 2015 UK guideline called for more research.6 In 
Scotland, about 15% of adults with type 1 diabetes have ever received metformin, with a typical 
prevalent use of about 8% (unpublished analysis of 2016 national data). 
Because metformin reduces risk of CVD in type 2 diabetes,9,10 we hypothesised that it might also 
have important cardiovascular as well as metabolic effects in type 1 diabetes. Progression of 
common carotid artery intima-media thickness (cIMT) is a surrogate of atherosclerosis11,12 that 
predicts future CVD events in the general population.13 Progression of cIMT was reduced in 
DCCT participants who were previously allocated to 6·5 years previous intensive glucose control 
in the first 6 years of EDIC follow-up and was associated with reduced CVD events 30 years 
from original randomisation.3,14 
We therefore initiated the REMOVAL study (REducing with MetfOrmin Vascular Adverse 
Lesions), an international, double-blind, randomised, placebo-controlled trial with the primary 
aim of testing whether 3 years of treatment with metformin 1000 mg twice daily added to titrated 
insulin therapy (towards target HbA1c 7·0% [53 mmol/mol]) reduces atherosclerosis, as 
measured by progression of cIMT, in adults with confirmed type 1 diabetes aged 40 years and 
older and at increased risk for CVD.15 
  
 Methods 
Study design and participants 
The design of REMOVAL, an international, randomised, parallel-group trial of metformin versus 
placebo in adults with type 1 diabetes, has been described previously.15 The study was done in 23 
hospital diabetes clinics in Australia, Canada, Denmark, the Netherlands, and the UK (17 initial 
sites plus six additional UK sites added in 2012 to meet recruitment targets). The protocol 
(appendix) was approved by the West of Scotland Research Ethics Service and relevant 
committees covering all sites.15 The University of Glasgow (Glasgow, UK) and NHS Greater 
Glasgow and Clyde (Glasgow, UK) were co-sponsors and specific responsibilities were 
delegated to international partner institutions. All participants provided written informed consent. 
Individuals aged 40 years or older with type 1 diabetes of at least 5 years' duration and at least 
three of the following ten specified CVD risk factors were eligible: BMI ≥27 kg/m2; current 
HbA1c >8·0% (64 mmol/mol); established CVD; strong family history of CVD (defined as at 
least one parent, biological aunt or uncle, or sibling with myocardial infarction, stroke, or a 
coronary artery bypass graft aged <60 years); current smoker; microalbuminuria (defined 
according to routine care screening systems at sites); estimated glomerular filtration rate (eGFR) 
<90 mL/min per 1·73m2; hypertension (blood pressure ≥140/90 mm Hg or established 
antihypertensive treatment); dyslipidaemia (total cholesterol ≥5·0 mmol/L, HDL cholesterol 
<1·2 mmol/L [men] or <1·3 mmol/L [women], triglycerides ≥1·7 mmol/L, or established lipid-
lowering treatment]); and diabetes duration >20 years (details in appendix p 7). Type 1 diabetes 
was defined in the initial protocol (version 1.0; June 23, 2011) as diagnosis of diabetes before 
age 35 years and insulin use within 1 year; the upper limit for age of diagnosis was revised to 40 
years in protocol version 2.0 (September, 2012) following review of screening logs (the 
requirement of type 1 diabetes duration of at least 5 years was retained). 
  
Randomisation and masking 
Following a 3 month run-in period with placebo masked to participants in the final month, 
participants who remained eligible (≥70% medication adherence and random C-peptide ≤0·2 
nmol/L at enrolment) were randomly assigned to receive metformin or placebo for 3 years. The 
placebo and active drug were identical in formulation (including excipients) and matched in 
shape and colour. Follow-up was abbreviated by between 1 and 8 months for the final 50 
participants, in accordance with the final protocol (version 3.0; Nov 9, 2015). After confirming 
entry criteria, randomisation was achieved via an interactive voice response system hosted by the 
study data centre at the Robertson Centre for Biostatistics (Glasgow Clinical Trials Unit), 
University of Glasgow, Glasgow, UK. The randomisation list was generated by use of a pseudo-
random number generator. Randomisation was stratified by study site, based on randomly 
permuted blocks allocated within each trial centre. Staff who generated the randomisation 
sequence had no role in any other part of the trial. Participants and site staff were fully masked to 
group assignment and all analyses predefined in the statistical analysis plan were programmed by 
investigators who were masked to treatment allocation. 
Procedures 
During the run-in period, CVD risk factor management was optimised in accordance with local 
guidelines at sites and insulin regimens were reviewed with the aim of optimising glycaemic 
control (target HbA1c 7·0% [53 mmol/mol]) with additional clinic visits if necessary. A 
randomisation visit (fasting) was then scheduled for baseline assessments including cIMT, 
endothelial function, and non-mydriatic colour retinal digital photographs. Study medication was 
either oral metformin hydrochloride 1000 mg twice daily with food (as Glucophage 500 mg) or 
placebo, provided free of charge by Merck KGaA (Darmstadt, Germany), and dispensed in 
identical packages with sufficient supply for 3 or 6 months, dependent on the visit schedule. 
Participants were given instructions on up-titrating study medication on a weekly basis from one 
tablet daily to two tablets twice daily (with meals) in week 4, with support from telephone visits. 
Lower doses were permitted for participants if adverse events occurred on higher doses. 
Adjustments in insulin doses towards target HbA1c were made at the discretion of site staff rather 
than being specified by the protocol. Study visits were scheduled to coincide with routine care 
appointments when possible; main study outcomes were reassessed at 12, 24, and 36 months. 
Participants continued to have access to usual local arrangements for diet, lifestyle, and weight 
management throughout the trial; ongoing management of glycaemia, blood pressure, and lipids 
was under the care of the site principal investigator and usual care team. A glycaemia committee 
sent detailed reports (masked to treatment allocation) on participants' HbA1c and rates of 
hypoglycaemia to each site every 6 months along with benchmarking data from other sites in 
their region. 
Outcomes 
The primary outcome was progression of averaged mean far-wall cIMT (measured in mm, at 
baseline, 12, 24, and 36 months). Right and left common carotid arteries were interrogated by B-
mode ultrasound with a 7·0 MHz or higher broadband linear array transducer, with concurrent 
recording of three-lead electrocardiograph. Longitudinal images were obtained at anterior, 
lateral, and posterior angles using Meijer's arc during at least five cardiac cycles. Centres were 
asked to submit six duplicate sets of scans for each annual study visit for assessment of quality 
control. The concordance correlation coefficient (CCC) for averaged mean far-wall cIMT was 
0·968 overall (ranging between 0·953 and 0·979 by visit). At the reading centre (University 
College London, London, UK), measurements were taken from the distal centimetre of the 
common carotid artery (ie, immediately proximal to the bulb) by a single trained assessor using a 
validated semi-automated programme. Repeat quality control cycles for the assessor yielded an 
overall CCC of 0·946 (ranging between 0·918 and 0·968). Individual measures of mean cIMT of 
greater than 1·5 mm, indicative of plaque, at any timepoint during follow-up were excluded from 
the primary outcome analysis, as recommended by the Mannheim consensus.16 
Secondary outcomes15 were: HbA1c, measured by local laboratories using DCCT-standardised 
assays; LDL cholesterol (measured centrally at the University of Glasgow); eGFR, calculated on 
the basis of serum creatinine measured by local laboratories by use of the Modification of Diet in 
Renal Disease Study equation; incident microalbuminuria among individuals who had 
normalbuminuria at baseline (on the basis of clinical history plus urine collection; this 
measurement was augmented by collection and storage of urine aliquots for later central analysis 
if indicated), the data for which are not reported in this paper for reasons stated in Results; 
incident retinopathy, defined as two or more step progression (concatenated) read from two-
colour 45° field photographs (field 1, optic disc; field 2, macula) taken from each eye at 
randomisation and at 36 months (graded with custom-designed software at the University of 
Wisconsin–Madison Ocular Epidemiology Reading Center [Madison, WI, USA] by use of the 
modified Airlie House classification scheme and the 11-step modified Early Treatment Diabetic 
Retinopathy Study [ETDRS] severity scale); bodyweight in kg (by calibrated scales); insulin 
dose (in units per kg); and endothelial function assessed at 0, 12, and 36 months as reactive 
hyperaemia index (RHI) in some study centres (14 centres provided data for endothelial function, 
covering 80% of participants) and read by staff masked to treatment allocation (EndoPAT, 
Itamar Medical, Caesarea, Israel). Improvement in two or more of the secondary outcomes was 
prespecified as clinically meaningful with the potential to affect clinical practice in the event of a 
positive primary outcome. 
Tertiary outcomes were: frequency of hypoglycaemia, assessed with the modified Steno 
Hypoglycaemia Questionnaire, in which events were classified as minor (self-treated, resolved 
with short-acting glucose and longer-acting carbohydrate) or major (requiring assistance from 
another person); treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire); 
biochemical markers of endothelial function (tissue plasminogen activator, sE-selectin, and 
sICAM-1), the data for which are not reported in this paper for reasons stated in the Results; 
progression of averaged maximal far-wall cIMT (in which plaque was included as 
recommended);14,17,18 and vitamin B12 status, as measured by local laboratories. 
For assessment of safety, data for incident diabetes-related complications, operations, or 
procedures and adverse events of medical significance (gastrointestinal, metabolic, and renal) 
that were not captured as outcomes were collected at each visit. Dose reduction of study 
medication was recommended per protocol if eGFR fell below 45 mL/min per 1·73m2 during 
follow-up. Specific thresholds for permanent discontinuation of study medication were stipulated 
by monitoring of biomarkers (alanine transaminase >3·0 times upper limit of normal; eGFR <30 
mL/min per 1·73m2; or serum lactate >5·0 mmol/L with acidosis or >3·0 mmol/L if confirmed 
by a mandated second measurement within 1 week). Participants whose vitamin B12 
concentrations fell below 150 pmol/L were offered the choice of treatment discontinuation or 
referral for supplementation. All serious adverse events were collected and reported in 
accordance with standard operating procedures. 
Statistical analysis 
Data management and statistical analyses were done at the study data centre (Robertson Centre 
for Biostatistics, University of Glasgow, Glasgow, UK).15 The study was designed, assuming 
mean cIMT progression of 0·044 mm over 3 years in the control group, to provide 90% power to 
detect a mean difference of 0·0167 mm (a third of an SD, assumed to be 0·05) in change from 
baseline of averaged mean far-wall cIMT between treatment groups (α=0·05), assuming 
enrolment of 500 participants and 20% loss to withdrawal or discontinuation of treatment. 
Analysis of the primary outcome was based on a repeated-measures random regression model 
assuming a general residual covariance structure with random intercepts and slopes, adjusted for 
baseline cIMT as well as for age, sex, smoking status, systolic blood pressure, BMI, HbA1c, and 
LDL cholesterol, and was therefore expected to provide additional power. Regression model 
effect estimates with 95% CIs and associated p values were calculated. The same approach was 
used for analysis of the tertiary cIMT outcome. For the primary outcome, prespecified sensitivity 
analyses were done as follows: to account for differences in ultrasound machines used at sites by 
adjusting for ultrasound probe frequency; based on a per-protocol analysis; and with multiple 
imputation of missing cIMT values. Analyses were done on a modified intention-to-treat basis, 
including all randomly assigned participants with post-randomisation data available for the 
outcome of interest at any given timepoint, irrespective of subsequent participation in the study 
or ongoing adherence to study medication. 
The sample size also provided 90% power to detect changes from baseline in the secondary 
outcomes of HbA1c, LDL cholesterol, eGFR, bodyweight, insulin dose, and endothelial function 
of about 0·3 SD (α=0·05). The retinopathy secondary outcome was likely to be underpowered 
because a 60% reduction in 3 year two-step or greater progression in the ETDRS severity scale 
was required to achieve 80% power. Outcomes were analysed as follows: ANCOVA, for change 
from baseline for continuous secondary and tertiary outcomes (HbA1c, LDL cholesterol, eGFR, 
bodyweight, insulin dose, endothelial function, and treatment satisfaction); Cox proportional-
hazards for occurrence of vitamin B12 concentration of less than 150 pmol/L (tertiary outcome); 
negative binomial regression models for rates of hypoglycaemia (tertiary outcome); and logistic 
regression analysis for two or more step progression of retinopathy (secondary outcome). The 
ANCOVA analyses were further extended, as prespecified, to include a visit-by-treatment 
interaction term to investigate whether the treatment effect varied over time. In the event of a 
significant interaction being found, the nature of the interaction was explored by plotting 
treatment effects over time. Comparisons between groups for the permanent discontinuations 
from study medication and the number of individuals who had at least one serious adverse event 
were made with χ2 tests. Analyses were done with SAS (version 9.3). No adjustments for 
multiple comparisons were prespecifed. 
No interim efficacy analyses were planned. An independent data monitoring committee reviewed 
unmasked reports on study progress every 6 months to monitor patient safety, the quality of 
efficacy information, and study conduct, as well as providing a recommendation to the sponsor 
on the appropriateness of continuing the study to completion. 
This trial is registered with ClinicalTrials.gov, number NCT01483560. 
Role of the funding source 
During planning of the study, the funder (JDRF) hosted workshops to discuss principles of trial 
design for adjunctive therapy in type 1 diabetes and to encourage funding applications; however, 
the funder had no role in data collection, data analysis, data interpretation, or writing of the 
report. Merck KGaA (which donated study medication) had no role in study design, data 
collection, data analysis, or data interpretation, but a representative was offered the opportunity 
to comment on the report before submission. The corresponding author and trial steering 
committee (appendix p 2) had full access to all study data and provided regular progress reports 
to the funder and pharmacovigilance reports to Merck KGaA. The corresponding author and trial 
steering committee had final responsibility for the decision to submit for publication. 
  
Results 
Between Dec 14, 2011, and June 24, 2014, 493 participants with type 1 diabetes were enrolled in 
a 3 month run-in with single-masked placebo in the final month. 428 individuals were 
subsequently randomly assigned, with 219 allocated to metformin and 209 to placebo (figure 1). 
Final data collection was on March 19, 2017. The characteristics of the treatment groups at 
randomisation were well balanced, and reflected the entry criteria requirement of at least three 
CVD risks factors. Across treatment groups, mean age was 55·5 years (SD 8·6), diabetes 
duration was 33·8 years (10·8), BMI was 28·5 kg/m2 (4·3), and HbA1c was 8·05% (0·82; 64·5 
mmol/mol [9·00]; table 1). 34% (145 of 428) of patients used insulin pump therapy, mean 
systolic and diastolic blood pressure were 129·5 mm Hg (SD 14·8) and 72·3 mm Hg (10·1), 
respectively (with 73% [313 of 428] on antihypertensive medication), and LDL cholesterol was 
2·2 mmol/L (0·71; with 82% [349 of 428] on a statin; table 1). 
The difference in mean within-person cIMT slopes (metformin relative to placebo) for the 
primary outcome (modified intention-to-treat analysis) was −0·005 mm per year (95% CI −0·012 
to 0·002; p=0·167; table 2, figure 2). There was no treatment-by-sex interaction (data not 
shown). All prespecified sensitivity analyses (to account for differences in ultrasound machines 
used at sites by adjusting for ultrasound probe frequency; based on a per-protocol analysis; and 
with multiple imputation of missing cIMT values) showed similar results (data not shown). 
Of the secondary outcomes (table 3, figure 3), HbA1c was reduced by metformin over 3 years 
(−0·13%, 95% CI −0·22 to −0·04; p=0·0060), but this was accounted for by a reduction at the 3-
month timepoint (−0·24%, −0·34 to −0·13; p<0·0001) that was not sustained thereafter 
(p=0·0163 for visit-by-treatment interaction). There was no reduction in insulin dose requirement 
on average over 3 years (−0·005 units per kg, 95% CI −0·022 to 0·012; p=0·5450), but there was 
evidence of a significant interaction between treatment and visit (units per kg; p=0·0018), with 
little difference between the treatment groups in the first 6 months, followed thereafter by a small 
but sustained reduction in patients allocated to metformin (estimated in post-hoc analyses as 
−0·023 units per kg, 95% CI −0·045 to −0·0005; p=0·045; figure 3). Differences favouring 
metformin were recorded in the mean within-person change between treatment groups in 
bodyweight (−1·17 kg, 95% CI −1·66 to −0·69; p<0·0001) and LDL cholesterol (−0·13 mmol/L, 
−0·24 to −0·03; p=0·0117); these changes would have met the secondary composite outcome (at 
least two of the secondary outcomes showing significant improvement) had the primary outcome 
shown a significant difference. There was also a significant increase in eGFR with metformin 
(4·00 mL/min per 1·73m2, 95% CI 2·19 to 5·81; p<0·0001; table 3, figure 3). There was no 
evidence of a treatment effect on endothelial function (as measured by RHI) or on retinopathy 
(table 3). We did not have adequate data for analysis of incident microalbuminuria at the time 
this report was prepared because medical history information was not well captured for patients 
with an eGFR of less than 90 mL/min per 1·73m2, insufficient local laboratory biochemical data 
were available to reliably ascertain microalbuminuria status in accordance with the protocol 
definition, and central analysis of stored urine aliquots had not yet been done. 
The tertiary cIMT outcome (averaged maximal) showed an increase over time in both treatment 
groups (table 2, figure 2), with reduced progression in association with metformin (difference in 
slope −0·013 mm per year, 95% CI −0·024 to −0·003; p=0·0093; figure 2, table 2). There was no 
difference between groups for minor or major hypoglycaemia, and no change in treatment 
satisfaction (table 4). Biochemical markers of endothelial function had not been measured at the 
time this report was prepared. 
59 (27%) participants on metformin and 26 (12%) on placebo discontinued treatment during the 
trial (table 4; p=0·0002; Kaplan-Meier plot in the appendix [p 9]). Discontinuation was due to 
gastrointestinal adverse effects in 34 (16%) participants on metformin and seven (3%) on 
placebo. The number of individuals who had at least one serious adverse event was similar 
between groups (34 [16%] patients on metformin vs 31 [15%] patients on placebo; p=0·8418; 
appendix p 8). 
Biochemical vitamin B12 deficiency (<150 pmol/L) was more frequent with metformin (table 4). 
Therapy was discontinued because of asymptomatic hyperlactataemia in four individuals on 
metformin and none on placebo; there were no cases of lactic acidosis. Five deaths occurred 
among patients allocated to metformin (three from cancer, two from cardiac disease) and two 
occurred among those allocated to placebo (one from cancer, one from cardiac disease; table 4); 
none were judged by site principal investigators to be related to study medication. No changes in 
blood pressure control were seen with metformin therapy (data not shown). 
Discussion 
Adding metformin to insulin therapy and standard of care for 3 years in adults with long-
standing type 1 diabetes and high cardiovascular risk did not significantly alter atherosclerosis 
progression as measured by the primary outcome (averaged mean cIMT) and did not have a 
sustained effect on glycaemic control. However, we did identify reductions in bodyweight, LDL 
cholesterol, and insulin dose requirement per unit of bodyweight, and a reduction in 
atherosclerosis progression as measured by the prespecified tertiary outcome of averaged 
maximal cIMT. Metformin was poorly tolerated by a substantial minority of participants, mainly 
because of gastrointestinal upset. 
Before REMOVAL, the longest trial of metformin versus placebo in patients with type 1 
diabetes was for 1 year in 100 individuals at the Steno Diabetes Center.19 Our systematic review 
of nine previous trials of metformin in type 1 diabetes (192·8 patient-years) provided some 
evidence for a reduction in insulin dose requirement (estimated at 6·6 units per day) when 
metformin was added to insulin.8 Bodyweight reduction was reported in three of six studies and 
HbA1c reduction in four of seven studies, but heterogeneous data for these outcomes could not be 
combined to give a pooled estimate of effect size.8 
In a recent trial by the US T1D Exchange group, 140 adolescents, over half of whom met criteria 
for obesity, were randomly assigned to metformin or placebo for 6 months. Metformin reduced 
bodyweight and caused a transient reduction in HbA1c at 13 weeks (−0·3%), which reverted to 
baseline by 26 weeks, with a mean reduction in insulin dose requirement with metformin of 0·1 
unit per kg (about 8 units per day) at both 13 and 26 weeks.20 This reduction was similar to the 
6·6 units per day noted in our systematic review,8 but about four times higher than seen during 
years 2 and 3 of REMOVAL (0·023 units per kg or about 1·9 units per day). This difference in 
findings might have been because baseline doses were almost twice as high in the T1D Exchange 
trial (1·1 vs 0·63–0·68 units per kg); notably, in the T1D Exchange trial, the difference was also 
detected earlier at 3 months rather than 6 months. 
The only trial of metformin in type 1 diabetes previously to have reported a reduction in LDL 
cholesterol (by 0·3 mmol/L) was the trial done at the Steno Diabetes Center,21 in which a much 
lower proportion of participants was treated with statins than in REMOVAL (about 37% vs 
82%), with a substantial imbalance at baseline favouring the metformin group. In REMOVAL, 
statin use was well balanced at baseline between groups. Although the effect size in REMOVAL 
was similarly small, it is likely to have been attenuated by treatment of LDL cholesterol to target 
in both groups in accordance with local guidelines. Despite the fairly small effect size, if this 
reduction in LDL cholesterol was sustained over decades (rather than the 3 years of the trial), it 
could have an effect on CVD outcomes in patients with type 1 diabetes. Although this effect 
could have been achieved by other means, from a global perspective it is relevant that generic 
metformin has a low acquisition cost. 
Metformin is associated with cardiovascular benefit in type 2 diabetes.9,10 These effects are not 
necessarily mediated by glucose lowering—eg, inhibition of STAT3 (and thereby monocyte-to-
macrophage differentiation) via activation of AMPK in vascular tissues has been implicated in a 
direct anti-atherosclerotic action of metformin.22 Moreover, metformin can improve aspects of 
endothelial function23 and inhibit formation of advanced glycation end products by binding and 
inactivating methylglyoxal via an AMPK-independent pathway.24 
Previous evidence that metformin can reduce atherosclerosis progression as measured by cIMT 
is inconsistent and based on underpowered, unblinded studies. Results of a double-blind, 
placebo-controlled trial in people without diabetes but with CVD showed no effect of metformin 
on mean cIMT.25 However, the mechanisms of atherosclerosis progression in type 1 diabetes 
might differ from those in other conditions. 
By design, participants in REMOVAL had increased CVD risk and about 12% had established 
CVD. However, progression of the primary outcome (averaged mean cIMT) in the placebo 
group was only about two-thirds of that predicted (0·030 mm vs 0·044 mm), perhaps because of 
high levels of risk-factor management with statins and antihypertensive drugs. By contrast, 
progression of the tertiary outcome, averaged maximal cIMT, was higher than in younger 
DCCT/EDIC participants, as was the reduction in maximal cIMT progression with metformin 
(−0·039 mm over 3 years in REMOVAL vs −0·013 to −0·019 mm over 5 years in 
DCCT/EDIC).14,26 Our selection of mean cIMT, which excludes individual readings greater than 
1·5 mm and plaque, as a primary outcome was driven by the aim of reducing variability in 
accordance with recommendations from the Mannheim consensus,16 although there is evidence 
of improved risk prediction with our tertiary outcome maximal cIMT, which might be more 
reflective of atherosclerosis progression than mean cIMT because it includes more advanced 
stages of disease, including focal thickening or plaque.26 
During DCCT and the early EDIC study, use of statins and antihypertensive drugs was 
uncommon in people with type 1 diabetes. Reduction in maximal cIMT in EDIC following 
previous intensive glucose control was later followed by a 30% reduction in CVD events over a 
total follow-up period of 30 years.3 It is premature to conclude that the effect of metformin on 
maximal cIMT in REMOVAL might translate to such substantial effects on clinical outcomes, 
especially in view of its status as a tertiary outcome. Notably, the contribution of reduced cIMT 
progression per se to lowered CVD outcome rates independent of glycaemia has not been 
formally explored in DCCT/EDIC. Conversely, although cIMT is simply a surrogate endpoint 
for downstream CVD events, the concordance in findings between trials that use cIMT 
progression and CVD outcomes is excellent, with a positive predictive value of 96%.11 
Our findings suggest that metformin might have direct effects on atherosclerosis progression in 
patients with type 1 diabetes, even in middle-aged individuals with long diabetes duration who 
are well treated with antihypertensive drugs and statins. In view of the absence of a persistent 
effect of metformin on HbA1c, this possible effect is unlikely to have been mediated by improved 
glycaemic control. Although an effect of metformin on endothelial function in conduit arteries 
has been reported in a double-masked, randomised, placebo-controlled pilot trial (n=42),27 we 
identified no effect in small resistance arteries using RHI in what was one of the largest studies 
of vascular function in type 1 diabetes to date. 
Although evidence from DCCT/EDIC implicates hyperglycaemia as the key driver of 
atherosclerosis and CVD in type 1 diabetes, renal disease also has an important role.3 In 
REMOVAL, mean eGFR fell by 4 mL/min per 1·73m2 over 3 years in the placebo group, as 
expected in this population. However, in the metformin group, it rose acutely within the first 
month and then followed a parallel trajectory to placebo until the end of the trial, at which point 
separation was maintained; eGFR was a prespecified secondary outcome, but this was an 
unexpected finding that we believe should not be overemphasised at this stage. We cannot assess 
whether decline in renal function was stabilised by metformin because eGFR was not 
remeasured after study medication was discontinued. Since metformin and creatinine share renal 
proximal tubule transport mechanisms,28 we speculate that metformin might acutely increase 
tubular excretion of creatinine, affecting its validity as a biomarker of renal function, although 
this phenomenon has not previously been described in metformin's 60 year history. Together 
with other recent data,29 these findings warrant further investigation. 
As the largest and longest clinical trial of metformin treatment in patients with type 1 diabetes to 
date, REMOVAL provides valuable information about its tolerability and safety. About a quarter 
of individuals (twice as many as in the placebo group) discontinued metformin over 3 years, 
suggesting that about one in eight had genuine intolerance, with the excess being attributable to 
gastrointestinal adverse effects. Although this finding potentially limits wider use of metformin 
in unselected individuals with type 1 diabetes, such intolerance is usually evident in the early 
months of use; additionally, prolonged-release metformin is available and has fewer 
gastrointestinal side-effects.30 
In terms of safety, the risk of biochemical vitamin B12 deficiency was more than doubled over 3 
years on metformin (12%) versus placebo (5%). Because vitamin B12 concentrations are not 
usually monitored in current practice, undetected clinically significant deficiency could develop 
over time, potentially contributing to sensory neuropathy in individuals already at risk. Our 
findings contribute to growing evidence that treatment with metformin reduces vitamin B12 
concentrations, suggesting that monitoring should be used during long-term use,7,31,32 particularly 
in type 1 diabetes, in which there is associated risk of gastroparesis, pernicious anaemia, and 
coeliac disease. We noted several cases of asymptomatic hyperlactataemia in patients treated 
with metformin and none in the placebo group; however, there were no cases of lactic acidosis 
and the clinical significance of this finding is uncertain. 
Limitations of the REMOVAL trial include use of an intermediate primary CVD outcome rather 
than a clinical one. Notably, no previous randomised trial of any intervention in type 1 diabetes 
has had a CVD primary outcome; despite the undoubted relevance of CVD in type 1 diabetes, 
REMOVAL is the first to include even a surrogate measure. The study was powered on the 
assumption that the SD of change from baseline for mean cIMT was 0·05, but despite central 
reading and an ongoing quality assurance programme, the observed value was 0·09. Although 
additional power is likely to have been achieved because of our use of a repeated measures 
regression analysis and adjustment for baseline characteristics, this increased SD probably 
reduced the statistical power of the trial. Moreover, we tested multiple secondary and tertiary 
outcomes (without adjustment for multiple comparisons), although all were prespecified. 
Strengths of the study include international recruitment in five countries and stable, modern 
glycaemic management, including insulin pump use by about a third of participants, increasing 
the generalisability of our findings. 
The results of REMOVAL do not support the assertion by current guidelines that metformin can 
improve glycaemic control in patients with type 1 diabetes, nor do they provide a rationale for 
restricting its use to those who are overweight or obese. However, they do suggest that wider off-
label use of metformin might be warranted to improve CVD risk management in type 1 diabetes, 
and possibly also reduce insulin dose requirement. 
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Table 1. Baseline characteristics 
    Metformin (n=219) Placebo (n=209) 
Age (years) 55·2 (8·5) 55·8 (8·8) 
Sex 
 Male 129 (59%) 124 (59%) 
 Female 90 (41%) 85 (41%) 
Ethnic origin* 
 White 215 (98%) 202 (97%) 
 Other 4 (2%) 7 (3%) 
Diabetes duration (years) 33·4 (11·0) 34·3 (10·5) 
C-peptide (nmol/L) 0·05 (0·03–0·10) 0·05 (0·03–0·10) 
Existing CVD 
 MI or stroke 17 (8%) 12 (6%) 
 All† 30 (14%) 22 (11%) 
 None 189 (86%) 187 (89%) 
Strong family history of CVD 
 Yes 60 (27%) 54 (26%) 
 No 159 (73%) 155 (74%) 
HbA1c 
 Absolute (mmol/mol) 64·8 (9·4) 64·1 (8·5) 
 % units 8·08 (0·86) 8·02 (0·78) 
Insulin regimen 
 Basal-bolus 128 (58%) 122 (58%) 
 Pump 73 (33%) 72 (34%) 
 Twice daily 5 (2%) 7 (3%) 
 Other 13 (6%) 8 (4%) 
    Metformin (n=219) Placebo (n=209) 
Total daily insulin dose (units per kg) 
 Basal-bolus 0·67 (0·23) 0·74 (0·29) 
 Pump 0·54 (0·29) 0·57 (0·29) 
 Twice daily 0·73 (0·35) 0·64 (0·27) 
 Other 0·67 (0·23) 0·73 (0·26) 
 All 0·63 (0·26) 0·68 (0·30) 
BMI (kg/m2) 28·4 (4·5) 28·5 (4·1) 
BMI category 
 Not overweight 50 (23%) 44 (21%) 
 Overweight 103 (47%) 96 (46%) 
 Obese 65 (30%) 69 (33%) 
 Unavailable 1 (<1%) 0 
Waist circumference (cm) 
 Men 99·6 (11·6) 100·0 (9·1) 
 Women 92·1 (12·2) 91·5 (12·1) 
Systolic blood pressure (mm Hg) 130·5 (15·0) 128·5 (14·6) 
Diastolic blood pressure (mm Hg) 73·1 (9·9) 71·5 (10·3) 
Total cholesterol (mmol/L) 4·03 (0·88) 4·01 (0·93) 
 LDL cholesterol (mmol/L) 2·23 (0·70) 2·25 (0·72) 
 HDL cholesterol (mmol/L) 1·64 (0·56) 1·62 (0·59) 
 Triglycerides (mmol/L) 1·07 (0·77) 1·03 (0·57) 
Smoking history 
 Current 35 (16%) 22 (11%) 
 Former 73 (33%) 71 (34%) 
 Never 111 (51%) 116 (56%) 
eGFR (mL/min/1·73m2) 92·9 (20·9) 91·1 (21·6) 
    Metformin (n=219) Placebo (n=209) 
Renal 
 Normal 
   (>90 mL/min/1·73m2) 128 (58%) 130 (62%) 
 Stage 1 CKD 
  (>90 mL/min/1·73m2) 
   Microalbuminuria 14 (6%) 14 (7%) 
   Proteinuria‡ 11 (5%) 8 (4%) 
 Stage 2 CKD§ 
  (60–89 mL/min/1·73m2) 59 (27%) 48 (23%) 
 Stage 3a CKD§ 
  (45–59 mL/min/1·73m2) 7 (3%) 9 (4%) 
Diabetic retinopathy¶ 
 None 26 (12%) 16 (8%) 
 Non-proliferative 140 (64%) 132 (63%) 
 Inactive proliferative 36 (16%) 39 (19%) 
 Active proliferative 15 (7%) 19 (9%) 
 Ungradable or missing 2 (1%) 3 (1%) 
Neuropathy‖ 23 (11%) 28 (13%) 
Antihypertensive drugs 
 Any 156 (71%) 157 (75%) 
  Angiotensin-converting enzyme inhibitor 111 (51%) 103 (49%) 
  Angiotensin-receptor blocker 43 (20%) 49 (23%) 
  Calcium-channel blocker 30 (14%) 38 (18%) 
  β blocker 19 (9%) 19 (9%) 
  α blocker 5 (2%) 7 (3%) 
Statin 180 (82%) 169 (81%) 
    Metformin (n=219) Placebo (n=209) 
Antiplatelet drugs 
 Aspirin 71 (32%) 80 (38%) 
 Clopidogrel 10 (5%) 6 (3%) 
Data are mean (SD), median (IQR), or n (%). Some percentages do not add up to 100% because 
of rounding. CVD=cardiovascular disease. MI=myocardial infarction. eGFR= estimated 
glomerular filtration rate. CKD=chronic kidney disease.* Data from self-report. †Includes a self-
reported history of MI, stroke, heart failure, coronary artery bypass graft or stent, angina, 
transient ischaemic attack, or peripheral vascular disease. ‡ Macroalbuminuria. § 
Microalbuminuria and proteinuria status not yet available for these CKD categories. ¶ Modified 
Airlie House Classification (worst eye). ‖ Impaired monofilament sensation. 
  
Table 2. Repeated measures analysis of cIMT 
  
Averaged mean far-wall cIMT 
(primary outcome) 
Averaged maximal far-wall cIMT 
(tertiary outcome) 
  Metformin Placebo 
Difference 
(95% CI); p 
value 
Metformin Placebo 
Difference 
(95% CI); p 
value 
Baseline 
(mm) 
0·773 
(0·140) 
0·791 
(0·183) 
.. 
0·910 
(0·162) 
0·926 
(0·225) 
.. 
12 months 
(mm) 
0·782 
(0·147) 
0·788 
(0·174) 
.. 
0·920 
(0·175) 
0·939 
(0·239) 
.. 
24 months 
(mm) 
0·792 
(0·145) 
0·823 
(0·187) 
.. 
0·936 
(0·161) 
0·984 
(0·251) 
.. 
36 months 
(mm) 
0·793 
(0·134) 
0·820 
(0·177) 
.. 
0·949 
(0·167) 
0·999 
(0·257) 
.. 
Main analysis* 
 
Slope 
(95% CI; 
mm per 
year) 
0·006 (0·001 
to 0·011) 
0·010 
(0·006 to 
0·015) 
−0·005 
(−0·012 to 
0·002); 
p=0·1664 
0·012 (0·005 
to 0·019) 
0·025 
(0·018 to 
0·032) 
−0·013 
(−0·024 to 
−0·003; 
p=0·0093) 
Data are mean (SD), unless otherwise indicated. Analyses are for modified intention-to-treat of 
participants with at least one measurement after baseline. cIMT=common carotid artery intima-
media thickness.* Adjusted for baseline age, sex, cIMT, smoking status, systolic blood pressure, 
BMI, HbA1c, and LDL cholesterol. 
  
Table 3. Secondary outcomes 
 Baseline 36 months 
Change 
(ANCOVA)*o
r OR†(95% 
CI) 
Main 
effect p 
value 
Interactio
n p value‡ 
 
Metformi
n 
Placeb
o 
Metformi
n 
Placeb
o 
   
HbA1c (%) 8·1 (0·9) 
8·0 
(0·8) 
8·1 (0·9) 
8·1 
(0·8) 
−0·13 (−0·22 
to −0·04)* 
0·0060 0·0163 
LDL cholesterol 
(mmol/L) 
2·23 
(0·70) 
2·25 
(0·72) 
2·07 
(0·83) 
2·21 
(0·71) 
−0·13 (−0·24 
to −0·03)* 
0·0117 0·3101 
eGFR 
(mL/min/1·73m2
) 
92·9 
(20·9) 
91·1 
(21·6) 
92·1 
(20·8) 
87·2 
(19·6) 
4·00 (2·19 to 
5·81)* 
<0·000
1 
0·6624 
Retinopathy (%; 
≥ two-step 
progression) 
..§ ..§ 8 (6) 10 (8) 
0·76 (0·29 to 
1·98)† 
0·5683 ..¶ 
Bodyweight (kg) 
83·9 
(15·4) 
83·5 
(13·7) 
82·0 
(15·4) 
83·2 
(13·8) 
−1·17 (−1·66 
to −0·69)* 
<0·000
1 
0·2736 
Insulin dose 
(units per kg) 
0·63 
(0·26) 
0·68 
(0·30) 
0·62 
(0·26) 
0·67 
(0·30) 
−0·005 
(−0·022 to 
0·012)* 
0·5450 0·0018 
Endothelial 
function (RHI; 
arbitrary units) 
2·28 
(0·74) 
2·24 
(0·75) 
2·17 
(0·69) 
2·24 
(0·73) 
−0·06 (−0·19 
to 0·06)* 
0·3016 0·5662 
Data are mean (SD) for continuous data or n (%) for categorical data. Treatment effect and 
corresponding 95% CIs are provided for metformin compared with placebo. eGFR=estimated 
glomerular filtration rate. RHI=reactive hyperaemia index.* ANCOVA for the change from 
baseline, adjusted for the baseline value, for continuous data. † Odds ratio (OR) and 95% CI for 
binary data obtained by logistic regression models. ‡ Visit-by-treatment interaction. § Refer to 
table 1 for baseline retinopathy data. ¶ No visit-by-treatment interaction term is available for 
retinopathy as it was assessed at only two visits (randomisation and close-out). 
 
  
Table 4. Tertiary outcomes, adherence, and safety 
   Baseline 36 months 
Change 
(ANCOVA)*or 
HR†/IRR‡(95% CI) 
p 
value 
   Metformin Placebo Metformin Placebo   
Tertiary outcomes 
Hypoglycaemia (per patient-year) 
 Minor events 37·2 38·8 54·6 49·1 1·12 (0·92 to 1·35)‡ 0·2594 
 Major events 0·15 0·17 0·16 0·14 1·23 (0·73 to 2·05)‡ 0·4419 
Treatment 
satisfaction (units) 
32·1 (3·6) 
31·4 
(4·2) 
31·8 (4·2) 
31·3 
(4·8) 
−0·12 (−0·72 to 
0·47)* 
0·6880 
Vitamin B12 <150 
pmol/L§ 
0 0 
24/194 
(12%) 
9/192 
(5%) 
2·76 (1·28 to 5·95)† 0·0094 
Adherence and safety 
Treatment 
discontinuation 
.. .. 59 (27%) 
26 
(12%) 
.. 0·0002 
 Gastrointestinal .. .. 34 (16%) 7 (3%) .. .. 
  Nausea .. .. 20 (9%) 5 (2%) .. .. 
  Diarrhoea .. .. 18 (8%) 3 (1%) .. .. 
 Reduced eGFR .. .. 0 0 .. .. 
 
Lactate >3·0 
mmol/L (twice) 
.. .. 1 (<1%) 0 .. .. 
 >5·0 mmol/L (any) .. .. 3 (1%) 0 .. .. 
Treatment down-
titration 
.. .. 67 (31%) 18 (9%) .. .. 
 
Study medication 
dose (mg per day) 
.. .. 1434 (612) 
1674 
(343) 
.. .. 
   Baseline 36 months 
Change 
(ANCOVA)*or 
HR†/IRR‡(95% CI) 
p 
value 
   Metformin Placebo Metformin Placebo   
 Lactate (mmol/L) 1·31 (0·76) 
1·23 
(0·57) 
1·30 (0·61) 
1·19 
(0·52) 
0·08 (−0·03 to 0·19)* 0·1640 
Deaths .. .. 5 (2%) 2 (1%) .. .. 
 Cancer .. .. 3¶ 1‖ .. .. 
 Cardiac .. .. 2** 1†† .. .. 
Data are mean (SD) for continuous data or n (%) for categorical data, unless otherwise indicated. 
Treatment effect and corresponding 95% CIs are provided for metformin compared with 
placebo. eGFR=estimated glomerular filtration rate. * ANCOVA for the change from baseline, 
adjusted for the baseline value, for continuous data. † Hazard ratio (HR) and 95% CI for time to 
first event data obtained by Cox proportional-hazards model. ‡ Incidence rate ratio (IRR) and 
95% CI for count data are obtained by negative binomial regression models, including the 
logarithm of time as an offset; the frequency of minor hypoglycaemia events is further adjusted 
for the method of collection. § Vitamin B12 data were missing for 25 people in the metformin 
group and 17 in the placebo group. ¶ Two non-small-cell lung cancers, one malignant neoplasm 
of the tongue. ‖ Glioblastoma. ** One myocardial infarction, one sudden cardiac death. †† 
Myocardial infarction. 
  
 Figure 1. Trial profile. cIMT=common carotid artery intima-media thickness. *One patient did 
not wish to proceed following a serious adverse event, one had a flare-up of irritable bowel 
syndrome, one withdrew because her husband became unwell, and one had a dislike of taking 
study medication. 
  
 Figure 2. Progression in (A) mean cIMT (primary outcome) and (B) maximal cIMT (tertiary 
outcome). Error bars show 95% CIs. cIMT=common carotid artery intima-media thickness (far 
wall). 
  
Figure 3. Changes from baseline in secondary outcomes. Mean change from baseline for up to 3 
years is shown for (A) HbA1c, (B) insulin dose requirement, (C) insulin dose requirement during 
first 6 months only, (D) LDL cholesterol, (E) bodyweight, and (F) estimated glomerular filtration 
rate (eGFR). Error bars show 95% CIs. 
